[Analysis of the efficacy of half-dose venetoclax combined with reduced-dose HA regimen in the induction therapy of acute myeloid leukemia].
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
We retrospectively analyzed clinical data on newly diagnosed acute myeloid leukemia (AML) patients who received HAV treatment between June 2020 and April 2023. The HAV regimen includes venetoclax at 100 mg on day 0 and 200 mg from day 1 to 14, administered orally; homoharringtonine at 2 mg/m(2) from day 3 to 9, given by intravenous infusion; and cytarabine at 50 mg/m(2) from day 3 to 9, also administered by intravenous infusion. Among 33 patients, 36.4% (12/33) were male, with a median age of 60 years (range, 14-67 years). The overall response rate after one cycle of induction therapy was 90.9%, and the complete response (CR) rate was 87.9%. Among the patients, 79.3% achieved CR with measurable residual disease negativity. No patient died during induction therapy. The median recovery times of neutrophils (≥1.0×10(9)/L) and platelets (≥30×10(9)/L) were 10 (5-12) days and 10 (3-13) days, respectively. Until October 30, 2024, the estimated 3-year overall survival rate, event-free survival rate, and disease-free survival rate were 68.2% (95% CI: 59.7% -76.7% ), 66.7% (95% CI: 58.5% -74.9% ), and 73.6% (95% CI: 65.6% -81.6% ), respectively. HAV is a highly effective and safe induction therapy regimen for patients with newly diagnosed AML.